Agenus Inc bought $25k of INKT
owner at MiNK Therapeutics, Inc.. 22,975 shares at an average of $1.10, traded Oct 12, 2023, filed Oct 16, 2023.
Score components
- +12Role10% owner
- +5Trade size$25k at market
- -5Relative to holdingsUnder 1% of holdings (0.1%)
- +8Price context66% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.3%, 3m -10.1%, 6m -17.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-23-053601, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 12, 2023 | POpen-market purchase Common Stock | +3,173 | $1.10 | $3,488 | 21,753,061 | Oct 16, 2023 |
| Oct 13, 2023 | POpen-market purchase Common Stock | +19,373 | $1.10 | $21k | 21,772,434 | Oct 16, 2023 |
| Oct 16, 2023 | POpen-market purchase Common Stock | +429 | $1.10 | $472 | 21,772,863 | Oct 16, 2023 |
Related signals
Other insiders at MiNK Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | INKTsell MiNK Therapeutics, Inc. | Barbara Ryan director | $19k 1,500 shares | -6% | |
| 15Weak | INKTsell MiNK Therapeutics, Inc. | Barbara Ryan director | $22k 1,500 shares | -7% | |
| 15Weak | INKTsell MiNK Therapeutics, Inc. | Barbara Ryan director | $5,426 500 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.